Joinn Laboratories (SHA:603127, HKG:6127) expects an attributable profit of between 600.1 million yuan and 900.2 million yuan for the first half of 2026, up 885% to 1,377% from 60.9 million yuan a year prior.
Revenue is expected to increase 0% to 10.5% to between 668.6 million yuan and 739 million yuan from 668.6 million yuan in the year-ago period, according to a Tuesday Hong Kong bourse filing.
The drug research company attributed the profit forecast to a rise in the market price, and organic growth and appreciation of biological assets, leading to positive changes in their fair value, as well as stable operating status from the company's laboratories.